SCHEMBL1483176

SCHEMBL1483176

CCn1cc(-c2ccc(C(=O)NC)cc2)nc1/C=C/c1ccc(-c2ccc(O)cc2)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MET P08581 1/20 0.41
HDAC6 Q9UBN7 5/20 0.41
USP7 Q93009 1/20 0.39
MEN1 O00255 1/20 0.38
GFER P55789 1/20 0.38
KMT2A Q03164 1/20 0.38
HDAC1 Q13547 5/20 0.38
HDAC4 P56524 2/20 0.38
HDAC3 O15379 1/20 0.38
HDAC7 Q8WUI4 1/20 0.38
HDAC2 Q92769 1/20 0.38
HDAC10 Q969S8 1/20 0.38
HDAC11 Q96DB2 1/20 0.38
HDAC8 Q9BY41 1/20 0.38
HDAC9 Q9UKV0 1/20 0.38
HDAC5 Q9UQL6 1/20 0.38
P2RY14 Q15391 1/20 0.38
KDM1A O60341 2/20 0.36
NPC1 O15118 2/20 0.36
RAB9A P51151 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1483177 1.00 MET (0.41) METHDAC6USP7MEN1GFER
SCHEMBL1481095 0.89 NPC1 (0.42) HDAC6MEN1KMT2AHDAC1HDAC4
SCHEMBL1480967 0.83 PPARA (0.42) HDAC6MEN1KMT2AHDAC1HDAC4
SCHEMBL1480964 0.83 PPARA (0.42) HDAC6MEN1KMT2AHDAC1HDAC4
SCHEMBL1482187 0.83 MEN1 (0.48) HDAC6MEN1GFERKMT2AHDAC1
SCHEMBL1482183 0.83 MEN1 (0.48) HDAC6MEN1GFERKMT2AHDAC1
SCHEMBL1481948 0.82 PLK1 (0.41) HDAC6MEN1KMT2AHDAC1HDAC4
SCHEMBL1481944 0.82 PLK1 (0.41) HDAC6MEN1KMT2AHDAC1HDAC4
SCHEMBL1481259 0.82 GFER (0.46) MEN1GFERKMT2AHDAC1P2RY14
SCHEMBL1481172 0.82 HSP90AA1 (0.44) HDAC6MEN1GFERKMT2AHDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110077399-A1 Substituted Azole Derivatives as Therapeutic Agents TRANSTECH PHARMA, INC. (US) 2011-03-31 US disclosed
US-20040192743-A1 Substituted azole derivatives as therapeutic agents TRANSTECH PHARMA, INC. 2004-09-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040192743-A1 Substituted azole derivatives as therapeutic agents PTPRS, PTPRO, PTPRJ MET 2705/4885HDAC6 1595/4885USP7 2299/4885
US-20110077399-A1 Substituted Azole Derivatives as Therapeutic Agents PTPRS, PTPRO, PTPRJ MET 2705/4885HDAC6 1595/4885USP7 2299/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.